TRABD2B: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TRABD2B. The page also collects GeneMedi's different modalities and formats products for TRABD2B in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TRABD2B target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
Enables Wnt-protein binding activity and metalloendopeptidase activity. Involved in several processes, including negative regulation of Wnt signaling pathway; positive regulation of protein oxidation; and positive regulation of protein-containing complex assembly. Is integral component of organelle membrane and integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]
Target ID | GM-SE1672 |
Target Name | TRABD2B |
Gene ID | 388630,666048,689914,712301,610174,101098071,787081,100063464 |
Gene Symbol and Synonyms | Gm12824,Hkat,RGD1564942,TIKI2,TRABD2B |
Uniprot Accession | A6NFA1 |
Uniprot Entry Name | TIKI2_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000269113 |
Target Classification | N/A |
Pre-made anti-TRABD2B inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TRABD2B benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRABD2B mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-TRABD2B monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Recombinant multi-species TIKI2/ TRABD2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TRABD2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
TRABD2B protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Pre-made TRABD2B viral vector in GM Promise-ORFTM
Cat No. | Products name | NM ID | Species | Type | Detail |
pGMLPm004487 | mouse Trabd2b Lentivirus plasmid | NM_001085549 | Mouse | Lentivirus plasmid | Detail |
vGMLPm004487 | mouse Trabd2b Lentivirus particle | NM_001085549 | Mouse | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.